Publications
83 publications
Funding
2 grants
Active
2 grants- Co-IW81XWH-19-1-0141Converting HR+ Breast Cancer Into an Individualized VaccineU.S. Department of Defense · 2019–2026
- Co-IW81XWH-21-2-0034Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectoryU.S. Department of Defense · 2021–2026
Clinical research
14 studies
Active
2 studies- PI24-082-NCP: ASPECT Study (Assessment of SIGNATERA genome PErformance across Cancer Types)Natera, Inc. · OPEN TO ACCRUAL (as of 2026)
- PINCT06401421EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual DiseaseExact Sciences Corporation · OPEN TO ACCRUAL (as of 2026)Breast Cancer
Completed & closed trials (12)
- PINCT04862663A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)PHASE3 · AstraZeneca, PLC · CLOSED TO ACCRUAL (as of 2026)Locally Advanced (Inoperable) or Metastatic Breast Cancer
- PINCT05374512A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)PHASE3 · AstraZeneca, PLC · IRB STUDY CLOSURE (as of 2026)Breast Cancer
- PINCT04316117FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATUREPHASE2 · ECOG-ACRIN Cancer Research Group · IRB STUDY CLOSURE (as of 2024)Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8
- PINCT05090358Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast CancerPHASE2 · Memorial Sloan Kettering Cancer Center · IRB STUDY CLOSURE (as of 2024)Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer
- PINCT03304080A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast CancerPHASE1; PHASE2 · Icahn School of Medicine at Mount Sinai · IRB STUDY CLOSURE (as of 2023)Breast Neoplasms; Breast Diseases
- PINCT04266249(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete ResponsePHASE2 · ECOG-ACRIN Cancer Research Group · CLOSED TO ACCRUAL (as of 2023)Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8
- PINCT04784715Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)PHASE3 · AstraZeneca, PLC · CLOSED TO ACCRUAL (as of 2023)Breast Cancer; HER2-positive; Metastatic
- PINCT04052555A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerPHASE1 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2023)Bilateral Breast Carcinoma; HER2-Negative Breast Carcinoma; Localized Breast Carcinoma; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma
- PINCT03725059A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)PHASE3 · Merck & Co., Inc. · CLOSED TO ACCRUAL (as of 2022)Breast Cancer
- PINCT01901094A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant ChemotherapyPHASE3 · Alliance for Clinical Trials in Oncology · CLOSED TO ACCRUAL (as of 2022)Stage II Breast Cancer; Stage IIIA Breast Cancer
- PINCT03734029A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsPHASE3 · Daiichi Sankyo, Inc. · IRB STUDY CLOSURE (as of 2021)Breast Cancer
- PINCT02954874A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant ChemotherapyPHASE3 · Southwest Oncology Group · CLOSED TO ACCRUAL (as of 2021)Breast Carcinoma In Situ; Invasive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
News mentions
1 mentionView all WCM news ↗
External relationships
Advisory/Scientific Board Member
Cardinal Health Foundation · Gilead Sciences, Inc. · Novartis Pharma AG · TerSera Therapeutics LLC